This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Live Chat: Fall Preview

BOSTON ( TheStreet) -- Welcome to September's Biotech Stock Live Chat. The floor is yours.

It's been a while since I did one of these chats, so a review of the ground rules: I'm here for the next 90 minutes to answer your biotech-investing questions and, hopefully, spark some interactive debate on the hot topics of the day. This chat only works if you participate, so please keep the questions and comments flowing.

If you're at a loss for topics, I have some suggestions that riff off my 2012 Biotech Stock Fall Preview.

With Vivus (VVUS) announcing the commercial launch of Qsymia on Monday, the weight-loss market share war with Arena Pharmaceuticals (ARNA) ratchets up a notch.

Amarin (AMRN - Get Report): NCE status, when? Vascepa launch? Takeout or partnership?

Let's debate Sunesis Pharmaceuticals (SNSS - Get Report) vs Cyclacel Pharmaceuticals (CYCC - Get Report). Which company has the better drug for acute myeloid leukemia?

Can Acadia Pharmaceuticals (ACAD - Get Report) and its Parkinson's disease drug pimavanserin succeed in the current phase III trial?

Can Exelixis (EXEL) or Ariad Pharmaceuticals (ARIA) garner early FDA approval for their respective cancer drugs?

Let's look ahead to see what's in store for hepatitis C drug stocks like Gilead Sciences (GILD), Idenix Pharmaceuticals (IDIX) and Vertex Pharmaceuticals (VRTX).

Will Peregrine Pharmaceuticals (PPHM - Get Report) sign a partner before starting the bavituximab phase III lung cancer study at year's end, as promised?

Sarepta Therapeutics (SRPT - Get Report)!

Let's talk about these stocks today, or any other biotech -investing subject that piques your interest. Please join me live.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
ACAD $35.67 0.00%
AMRN $1.89 0.00%
CYCC $0.89 0.00%
PPHM $1.31 0.00%
SNSS $2.26 0.00%

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs